People still being denied improved treatment for multidrug-resistant TB

MSF urges governments to step up the use of newer TB drugs

Guadalajara, Mexico, October 13, 2017 - People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is

Why India’s TB control is faltering: Poor diagnostics, drug supply disruptions and no counselling

India’s tuberculosis control programme is not fully equipped to prevent, diagnose, and treat patients. The Revised National Tuberculosis Control Program uses outdated diagnostic techniques, suffers from repeated medicine stock-outs and lacks capacity to counsel tuberculosis patients, according to the Out of Step report released by the Stop TB Partnership and Médecins Sans Frontières last week.

Tuberculosis: New report reveals that countries are still not tackling world’s deadliest infectious disease

Hamburg/Geneva, 5 July 2017 — Two days ahead of the G20 summit in Germany, the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership released the third edition of ‘Out of Step,’ a report highlighting the need for governments to increase efforts to combat tuberculosis (TB). The report reviews TB policies and practices in 29[1] countries – which account for 82% of the global TB burden – and shows that countries can do much more to prevent, diagnose and treat people affected by TB.

In India’s fight against tuberculosis, diagnostics remains poorly understood

While India houses the largest number – 27% – of the world’s 10.4 million new TB patients, Mumbai is the epicentre of the disease in the country. The metropolis has many overcrowded slums where about five people share a house like that of Patil’s. Such spaces are ideal for the TB bacteria to spread.


Click here to read more

Submitted by admin on March 23, 2017

Fewer than 5% of people in need are treated with new TB drugs, nearly four years after their approval

Companies and countries must take urgent action to increase access to these life-saving treatments

Geneva – Only 4,800 people with drug-resistant tuberculosis (DR-TB) in 2016 were treated with two newer and much more effective medicines, even though these have now been on the market for up to four years, Doctors Without Borders/Médecins Sans Frontières (MSF) deplored today. Outside of a small number of clinical trials and compassionate use programs, just 469 people received delamanid in 2016, while just over 4,300 received bedaquiline.

Submitted by admin on February 24, 2017

Swaziland: New hope for DR-TB patients

By Zanele Zwane, MSF Swaziland

“You see, I am healed. Even my legs don’t give me problems anymore. Now I can walk perfectly. I walk around the hospital; go out for fresh air and come back when I’m ready,” says an elated Tholakele as she walks around her ward demonstrating her recovery.  

Tholakele, 39, has drug-resistant tuberculosis (DR-TB) and started treatment in May 2016 at the MSF-supported Moneni National TB Hospital in central Swaziland.